[ { "evidence_id": "EV-0101", "claim": "SURMOUNT-1 reported mean weight reductions of 16.0%, 21.4% and 22.5% at 72 weeks versus 2.4% with placebo", "source_title": "Tirzepatide Once Weekly for the Treatment of Obesity", "source_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2206038", "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0101.png", "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0102", "claim": "SURMOUNT-5 reported \u221220.2% weight change with tirzepatide versus \u221213.7% with semaglutide at 72 weeks", "source_title": "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity", "source_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2416394", "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0102.png", "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0103", "claim": "SURMOUNT-OSA reported reductions in apnoea-hypopnoea index, weight, hypoxic burden, hsCRP and systolic blood pressure", "source_title": "Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity", "source_url": "https://www.nejm.org/doi/10.1056/NEJMoa2404881", "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0103.png", "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0104", "claim": "Three years of tirzepatide in obesity with prediabetes markedly lowered progression to type 2 diabetes versus placebo", "source_title": "Tirzepatide for Obesity Treatment and Diabetes Prevention", "source_url": "https://www.nejm.org/doi/abs/10.1056/NEJMoa2410819", "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0104.png", "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0105", "claim": "SURMOUNT-4 examined continued tirzepatide versus withdrawal for maintenance of weight reduction", "source_title": "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial", "source_url": "https://jamanetwork.com/journals/jama/fullarticle/2812936", "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0105.png", "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "Registry identifier, sample size and numeric results not yet captured from the full text. Do not publish result figures until they are." }, { "evidence_id": "EV-0201", "claim": "FDA proposed on 30 April 2026 to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need", "source_title": "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List", "source_url": "https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list", "source_type": "Federal agency press announcement", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0201.png", "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0202", "claim": "The formal notice appeared at 91 Fed. Reg. 23431 on 1 May 2026, docket 2026-08552", "source_title": "List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B", "source_url": "https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal", "source_type": "Federal Register notice", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0202.png", "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0203", "claim": "FDA extended the comment period; comments must be submitted by 30 July 2026", "source_title": "Comment period extension, List of Bulk Drug Substances Under Section 503B", "source_url": "https://www.federalregister.gov/documents/full_text/html/2026/06/26/2026-12937.html", "source_type": "Federal Register notice", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0203.png", "strength": "Primary", "status": "verified", "next_review": "2026-07-31", "notes": "Live deadline. Re-check on 31 July 2026 and again when a final determination publishes." }, { "evidence_id": "EV-0301", "claim": "NexLife publishes tirzepatide (standard subcutaneous) at $215/month on the month-to-month plan, $215 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide standard subcutaneous plans", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider's own published plan page", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0301.png", "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-24", "notes": null }, { "evidence_id": "EV-0302", "claim": "NexLife publishes tirzepatide (standard subcutaneous) at $195/month on the 3-month prepaid plan, $585 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide standard subcutaneous plans", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider's own published plan page", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0302.png", "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-24", "notes": null }, { "evidence_id": "EV-0303", "claim": "NexLife publishes tirzepatide (standard subcutaneous) at $190/month on the 6-month prepaid plan, $1140 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide standard subcutaneous plans", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider's own published plan page", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0303.png", "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-24", "notes": null }, { "evidence_id": "EV-0304", "claim": "NexLife publishes tirzepatide (standard subcutaneous) at $186/month on the 12-month prepaid plan, $2232 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide standard subcutaneous plans", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider's own published plan page", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0304.png", "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-24", "notes": null }, { "evidence_id": "EV-0305", "claim": "NexLife publishes semaglutide (standard subcutaneous) at $165/month on the month-to-month plan, $165 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide standard subcutaneous plans", "source_url": "https://nexlife.us/pages/semaglutide-all-plans", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0306", "claim": "NexLife publishes semaglutide (standard subcutaneous) at $149/month on the 3-month prepaid plan, $447 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide standard subcutaneous plans", "source_url": "https://nexlife.us/pages/semaglutide-all-plans", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0307", "claim": "NexLife publishes semaglutide (standard subcutaneous) at $147/month on the 6-month prepaid plan, $882 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide standard subcutaneous plans", "source_url": "https://nexlife.us/pages/semaglutide-all-plans", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0308", "claim": "NexLife publishes semaglutide (standard subcutaneous) at $145/month on the 12-month prepaid plan, $1740 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide standard subcutaneous plans", "source_url": "https://nexlife.us/pages/semaglutide-all-plans", "source_type": "Provider's own published plan page", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0308.png", "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-24", "notes": null }, { "evidence_id": "EV-0309", "claim": "NexLife publishes tirzepatide (microdose) at $189/month on the month-to-month plan, $189 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide microdose plans", "source_url": "https://nexlife.us/pages/microdose-tirzepatide-program", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0310", "claim": "NexLife publishes tirzepatide (microdose) at $159/month on the 3-month prepaid plan, $479 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide microdose plans", "source_url": "https://nexlife.us/pages/microdose-tirzepatide-program", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0311", "claim": "NexLife publishes tirzepatide (microdose) at $150/month on the 6-month prepaid plan, $899 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide microdose plans", "source_url": "https://nexlife.us/pages/microdose-tirzepatide-program", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0312", "claim": "NexLife publishes tirzepatide (microdose) at $147/month on the 12-month prepaid plan, $1764 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide microdose plans", "source_url": "https://nexlife.us/pages/microdose-tirzepatide-program", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0313", "claim": "NexLife publishes semaglutide (microdose) at $129/month on the month-to-month plan, $129 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide microdose plans", "source_url": "https://nexlife.us/pages/microdose-semaglutide-program", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0314", "claim": "NexLife publishes semaglutide (microdose) at $117/month on the 3-month prepaid plan, $357 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide microdose plans", "source_url": "https://nexlife.us/pages/microdose-semaglutide-program", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0315", "claim": "NexLife publishes semaglutide (microdose) at $114/month on the 6-month prepaid plan, $684 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide microdose plans", "source_url": "https://nexlife.us/pages/microdose-semaglutide-program", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0316", "claim": "NexLife publishes semaglutide (microdose) at $110/month on the 12-month prepaid plan, $1320 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide microdose plans", "source_url": "https://nexlife.us/pages/microdose-semaglutide-program", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0317", "claim": "NexLife publishes tirzepatide (sublingual ODT) at $229/month on the month-to-month plan, $229 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide sublingual ODT plans", "source_url": "https://nexlife.us/pages/sublingual-tirzepatide-odt", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0318", "claim": "NexLife publishes tirzepatide (sublingual ODT) at $219/month on the 3-month prepaid plan, $657 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide sublingual ODT plans", "source_url": "https://nexlife.us/pages/sublingual-tirzepatide-odt", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0319", "claim": "NexLife publishes tirzepatide (sublingual ODT) at $205/month on the 6-month prepaid plan, $1230 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide sublingual ODT plans", "source_url": "https://nexlife.us/pages/sublingual-tirzepatide-odt", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0320", "claim": "NexLife publishes tirzepatide (sublingual ODT) at $199/month on the 12-month prepaid plan, $2388 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide sublingual ODT plans", "source_url": "https://nexlife.us/pages/sublingual-tirzepatide-odt", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0321", "claim": "NexLife publishes semaglutide (sublingual ODT) at $199/month on the month-to-month plan, $199 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide sublingual ODT plans", "source_url": "https://nexlife.us/pages/sublingual-semaglutide-odt", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0322", "claim": "NexLife publishes semaglutide (sublingual ODT) at $185/month on the 3-month prepaid plan, $597 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide sublingual ODT plans", "source_url": "https://nexlife.us/pages/sublingual-semaglutide-odt", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0323", "claim": "NexLife publishes semaglutide (sublingual ODT) at $177/month on the 6-month prepaid plan, $1062 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide sublingual ODT plans", "source_url": "https://nexlife.us/pages/sublingual-semaglutide-odt", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0324", "claim": "NexLife publishes semaglutide (sublingual ODT) at $165/month on the 12-month prepaid plan, $1980 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide sublingual ODT plans", "source_url": "https://nexlife.us/pages/sublingual-semaglutide-odt", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0350", "claim": "NexLife states it is LegitScript-certified", "source_title": "NexLife published website content", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider claim", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Provider-reported", "status": "reported", "next_review": "2026-08-24", "notes": "Verify directly in the LegitScript certification lookup, not on the provider's own page." }, { "evidence_id": "EV-0351", "claim": "NexLife states it works exclusively with LegitScript-certified, NABP-accredited pharmacies", "source_title": "NexLife published website content", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider claim", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Provider-reported", "status": "reported", "next_review": "2026-08-24", "notes": "Name the specific pharmacy or pharmacies and verify each accreditation with the accrediting body." }, { "evidence_id": "EV-0352", "claim": "NexLife states every batch undergoes independent third-party testing for potency, sterility, pH and endotoxin", "source_title": "NexLife published website content", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider claim", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Provider-reported", "status": "reported", "next_review": "2026-08-24", "notes": "Ask who performs the testing, whether a certificate of analysis is available to patients, and for a sample COA." }, { "evidence_id": "EV-0353", "claim": "NexLife states compounded medication is prepared by U.S.-licensed 503A compounding pharmacies", "source_title": "NexLife published website content", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider claim", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Provider-reported", "status": "reported", "next_review": "2026-08-24", "notes": "One NexLife page references 503A; third-party coverage references both 503A and 503B. Resolve which applies, because the regulatory position and the pending FDA 503B bulks proposal differ materially between them." }, { "evidence_id": "EV-0354", "claim": "NexLife states availability in all 50 states", "source_title": "NexLife published website content", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider claim", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Provider-reported", "status": "reported", "next_review": "2026-08-24", "notes": "Verify state by state against checkout or written support confirmation. A national marketing claim is not evidence of availability in any specific state." }, { "evidence_id": "EV-0355", "claim": "NexLife cites SURMOUNT-1 as showing average weight loss of up to 24.3% over 72 weeks", "source_title": "NexLife published website content", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider claim", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Provider-reported", "status": "reported", "next_review": "2026-08-24", "notes": "The SURMOUNT-1 efficacy-estimand results published in NEJM were 16.0%, 21.4% and 22.5% at 5, 10 and 15 mg. Establish which analysis the 24.3% figure comes from before repeating it. Separately, SURMOUNT-1 studied the FDA-approved product, not a compounded preparation, so the result does not transfer automatically." }, { "evidence_id": "EV-0356", "claim": "NexLife references self-reported outcomes from 518 members", "source_title": "NexLife published website content", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider claim", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Provider-reported", "status": "reported", "next_review": "2026-08-24", "notes": "Self-reported member data is not trial evidence. If cited at all, label it as self-reported, state the denominator and response rate, and never present it beside trial figures without that distinction." }, { "evidence_id": "EV-0106", "claim": "SUMMIT reported a 38% reduction in the combined endpoint of death and worsening heart-failure events in obesity-related HFpEF", "source_title": "Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy", "source_url": "https://www.jacc.org/doi/10.1016/j.jacc.2024.11.001", "source_type": "Peer-reviewed substudy of a randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0106.png", "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "Capture the primary SUMMIT publication DOI and the absolute event rates before publishing the relative risk reduction alone." }, { "evidence_id": "EV-0107", "claim": "Retatrutide phase 3 figures circulating in commercial secondary sources are unconfirmed against a primary publication", "source_title": "Retatrutide phase 2 trial", "source_url": "https://doi.org/10.1056/NEJMoa2301972", "source_type": "Peer-reviewed randomised controlled trial (phase 2)", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary for phase 2 only", "status": "reported", "next_review": "2026-08-24", "notes": "Several sites publishing phase 3 retatrutide figures are peptide vendors or carry provider advertising inside clinical copy. Treat as unverified." }, { "evidence_id": "EV-04001", "claim": "Found lists tirzepatide (compounded injectable) at $169 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04002", "claim": "NexLife lists tirzepatide (compounded injectable) at $186 per month, total including any required membership", "source_title": "NexLife published self-pay programme pages", "source_url": null, "capture_date": "2026-07-11", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "Standard injection, 12-month plan ($2,232). 6-month $190; 3-month $195; month-to-month $215. No membership fee, flat at every covered dose.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04003", "claim": "Oak Longevity lists tirzepatide (compounded injectable) at $199 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04004", "claim": "Shed lists tirzepatide (compounded injectable) at $245 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04005", "claim": "Mochi Health lists tirzepatide (compounded injectable) at $278 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04006", "claim": "Enhance.MD lists tirzepatide (compounded injectable) at $280 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04007", "claim": "Eden lists tirzepatide (compounded injectable) at $298 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04008", "claim": "Noom Med lists tirzepatide (compounded injectable) at $299 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04009", "claim": "TrimRx lists tirzepatide (compounded injectable) at $349 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04010", "claim": "MEDVi lists tirzepatide (compounded injectable) at $399 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": null, "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "pending", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04011", "claim": "bmiMD lists tirzepatide (compounded injectable) at $399 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04012", "claim": "NexLife lists tirzepatide (compounded microdose) at $147 per month, total including any required membership", "source_title": "NexLife published self-pay programme pages", "source_url": null, "capture_date": "2026-07-11", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "Microdose, 12-month plan ($1,764). Month-to-month $189; 6-month $150; 3-month $160. Below every dose studied in the trials.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04013", "claim": "Enhance.MD lists tirzepatide (compounded microdose) at $169 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04014", "claim": "Shed lists tirzepatide (compounded microdose) at $199 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04015", "claim": "bmiMD lists tirzepatide (compounded microdose) at $349 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04016", "claim": "NexLife lists tirzepatide (compounded oral / ODT) at $199 per month, total including any required membership", "source_title": "NexLife published self-pay programme pages", "source_url": null, "capture_date": "2026-07-11", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "ODT, 12-month plan ($2,388). Month-to-month $229; 6-month $205; 3-month $219. No trial has tested this dosage form.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04017", "claim": "Henry Meds lists tirzepatide (compounded oral / ODT) at $349 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04018", "claim": "NexLife lists semaglutide (compounded microdose) at $110 per month, total including any required membership", "source_title": "NexLife published self-pay programme pages", "source_url": null, "capture_date": "2026-07-11", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "Microdose, 12-month plan ($1,320). Month-to-month $129; 6-month $114; 3-month $119. Below every dose studied in the trials.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04019", "claim": "Shed lists semaglutide (compounded microdose) at $149 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04020", "claim": "Oak Longevity lists semaglutide (compounded injectable) at $133 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04021", "claim": "NexLife lists semaglutide (compounded injectable) at $145 per month, total including any required membership", "source_title": "NexLife published self-pay programme pages", "source_url": null, "capture_date": "2026-07-11", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "Standard injection, 12-month plan ($1,740). Month-to-month $165; 6-month $147; 3-month $149. No membership fee, flat at every covered dose.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04022", "claim": "Found lists semaglutide (compounded injectable) at $169 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04023", "claim": "Shed lists semaglutide (compounded injectable) at $175 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04024", "claim": "Mochi Health lists semaglutide (compounded injectable) at $178 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04025", "claim": "Eden lists semaglutide (compounded injectable) at $198 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04026", "claim": "Noom Med lists semaglutide (compounded injectable) at $199 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04027", "claim": "TrimRx lists semaglutide (compounded injectable) at $199 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04028", "claim": "Enhance.MD lists semaglutide (compounded injectable) at $212 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04029", "claim": "bmiMD lists semaglutide (compounded injectable) at $289 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04030", "claim": "Henry Meds lists semaglutide (compounded injectable) at $297 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04031", "claim": "MEDVi lists semaglutide (compounded injectable) at $299 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04032", "claim": "NexLife lists semaglutide (compounded oral / ODT) at $165 per month, total including any required membership", "source_title": "NexLife published self-pay programme pages", "source_url": null, "capture_date": "2026-07-11", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "ODT, 12-month plan ($1,980). Month-to-month $199; 6-month $177; 3-month $185. No trial has tested this dosage form.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04033", "claim": "Henry Meds lists semaglutide (compounded sublingual) at $179 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04034", "claim": "Shed lists semaglutide (compounded sublingual) at $199 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04035", "claim": "Shed lists semaglutide (compounded sublingual) at $229 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04036", "claim": "Henry Meds lists semaglutide (compounded oral / ODT) at $249 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04037", "claim": "MEDVi lists semaglutide (compounded oral / ODT) at $369 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": null, "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "pending", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04038", "claim": "Found lists liraglutide (compounded injectable) at $169 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04039", "claim": "Henry Meds lists liraglutide (compounded injectable) at $179 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04040", "claim": "LillyDirect lists orforglipron (Foundayo) (brand oral, FDA-approved) at $149 per month, total including any required membership", "source_title": "Manufacturer self-pay pricing page", "source_url": null, "capture_date": "2026-07-06", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "0.8 mg starter, Self Pay Journey Program. Rises to $199 (2.5 mg), $299 (5.5/9 mg), $349 (14.5/17.2 mg); drops to $299 on refill within 45 days.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04041", "claim": "NovoCare Pharmacy lists semaglutide (Wegovy tablets) (brand oral, FDA-approved) at $149 per month, total including any required membership", "source_title": "Manufacturer self-pay pricing page", "source_url": null, "capture_date": "2026-07-06", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "Wegovy tablets, 1.5 mg and 4 mg.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04042", "claim": "LillyDirect lists tirzepatide (Zepbound) (brand injectable, FDA-approved) at $299 per month, total including any required membership", "source_title": "Manufacturer self-pay pricing page", "source_url": null, "capture_date": "2026-07-06", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "2.5 mg starter vial, Self Pay Journey Program. 5 mg $399; 7.5\u201315 mg $449, requiring refill within 45 days to hold the rate.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04043", "claim": "NovoCare Pharmacy lists semaglutide (Wegovy) (brand injectable, FDA-approved) at $349 per month, total including any required membership", "source_title": "Manufacturer self-pay pricing page", "source_url": null, "capture_date": "2026-07-06", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "Month three onward, all maintenance doses. Reduced from $499 in November 2025.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04044", "claim": "PlushCare lists tirzepatide (Zepbound) (brand injectable, FDA-approved) at $319 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04045", "claim": "WeightWatchers Clinic lists semaglutide (Wegovy) (brand injectable, FDA-approved) at $323 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04046", "claim": "Hims lists semaglutide (Wegovy tablets) (brand oral, FDA-approved) at $298 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04047", "claim": "Ro lists semaglutide (Wegovy) (brand injectable, FDA-approved) at $348 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04048", "claim": "Found lists tirzepatide (Zepbound) (brand injectable, FDA-approved) at $447 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04049", "claim": "Eden lists semaglutide (Wegovy) (brand injectable, FDA-approved) at $1794 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04050", "claim": "Hers lists tirzepatide (Mounjaro) (brand injectable, FDA-approved) at $2048 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-0108", "claim": "SURMOUNT-3 reported \u221218.4% additional weight reduction after a lifestyle lead-in versus +2.5% placebo", "source_title": "Wadden TA et al., Nature Medicine 2023", "source_url": null, "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "reported", "next_review": "2026-10-24", "notes": "Retrieve and archive the full text; record DOI and PMID.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-0109", "claim": "SURMOUNT-4 reported 5.5% further loss on continued treatment against 14.0% regain after withdrawal", "source_title": "Aronne LJ et al., JAMA 2024", "source_url": null, "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "reported", "next_review": "2026-10-24", "notes": "Retrieve and archive the full text; record DOI and PMID.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-0110", "claim": "SURPASS-2 reported HbA1c reductions of 2.01\u20132.30% with tirzepatide versus 1.86% with semaglutide 1 mg", "source_title": "Fr\u00edas JP et al., N Engl J Med 2021", "source_url": null, "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "reported", "next_review": "2026-10-24", "notes": "Retrieve and archive the full text; record DOI and PMID.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-0111", "claim": "SURPASS-CVOT found tirzepatide non-inferior to dulaglutide for major adverse cardiovascular events", "source_title": "SURPASS-CVOT, 2024", "source_url": null, "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "reported", "next_review": "2026-10-24", "notes": "Retrieve and archive the full text; record DOI and PMID.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-0112", "claim": "SURMOUNT-1 publishes two estimands; the treatment-regimen figures are 15.0/19.5/20.9% and the efficacy figures are 16.0/21.4/22.5%", "source_title": "Jastreboff AM et al., N Engl J Med 2022", "source_url": null, "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "reported", "next_review": "2026-10-24", "notes": "Retrieve and archive the full text; record DOI and PMID.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-0501", "claim": "The Federation of State Medical Boards maintains a public directory of every state medical board", "source_title": "FSMB \u2014 Contact a State Medical Board", "source_url": "https://www.fsmb.org/contact-a-state-medical-board/", "source_type": "National regulatory federation directory", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "FSMB represents 70 state medical and osteopathic boards across the US, its territories and DC." }, { "evidence_id": "EV-0502", "claim": "The National Association of Boards of Pharmacy maintains a public directory of state boards of pharmacy", "source_title": "NABP \u2014 Contact Your Board", "source_url": "https://nabp.pharmacy/about/boards-of-pharmacy/", "source_type": "National regulatory association directory", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "Active member boards cover all 50 states, DC, Guam, Puerto Rico and the Virgin Islands." }, { "evidence_id": "EV-0113", "claim": "Orforglipron (Foundayo) was FDA-approved on 1 April 2026 for chronic weight management, with reported mean weight reduction of approximately 11% to 12.4% at the highest dose over 72 weeks", "source_title": "FDA approves Lilly's Foundayo (orforglipron)", "source_url": "https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill", "source_type": "Manufacturer announcement", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Manufacturer announcement. The efficacy figure varies between 11% and 12.4% across sources without a consistently stated estimand. Capture the ATTAIN-1 publication before charting a single number." }, { "evidence_id": "EV-0114", "claim": "OASIS 4 reported 13.6% mean weight reduction on the treatment-policy estimand and 16.6% among adherent participants, against 2.2% and 2.7% with placebo", "source_title": "Wharton S et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med 2025;393(11):1077-1087", "source_url": "https://doi.org/10.1056/NEJMoa2500969", "source_type": "Trade press", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0115", "claim": "The Wegovy pill (oral semaglutide 25 mg) was FDA-approved on 22 December 2025 for weight management and for reducing the risk of major adverse cardiovascular events", "source_title": "Novo Nordisk: Wegovy pill approved in the US as first oral GLP-1 for weight management", "source_url": "https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916472", "source_type": "Manufacturer announcement", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0116", "claim": "LillyDirect self-pay pricing for Foundayo runs $149 to $349 by dose, with $299 on the top two doses when timely refill requirements are met; $25 per month with an eligible commercial savings card and $50 for eligible Medicare Part D patients from 1 July 2026", "source_title": "FDA Approves Lilly's Oral GLP-1 Orforglipron for Obesity", "source_url": "https://www.ajmc.com/view/fda-approves-lilly-s-oral-glp-1-orforglipron-for-obesity", "source_type": "Manufacturer announcement", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Trade press reporting of manufacturer pricing. Re-capture from LillyDirect's own page before describing as verified." }, { "evidence_id": "EV-0601", "claim": "FDA states that registration as an outsourcing facility means only that the agency has received the required information. It does not mean the facility is making FDA-approved drugs, and it does not mean the facility is in compliance with CGMP requirements or the other conditions of section 503B", "source_title": "Questions and Answers: Outsourcing Facility Registration", "source_url": "https://www.fda.gov/drugs/human-drug-compounding/questions-and-answers-outsourcing-facility-registration", "source_type": "Federal agency guidance", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "This is the agency's own wording and it is stronger than the common summary. CGMP compliance is a legal requirement under 503B; registration is not evidence that a given facility meets it." }, { "evidence_id": "EV-0602", "claim": "FDA maintains a public register of outsourcing facilities and a searchable Outsourcing Facility Product Report database covering the last four reporting periods", "source_title": "Information for Outsourcing Facilities", "source_url": "https://www.fda.gov/drugs/human-drug-compounding/information-outsourcing-facilities", "source_type": "Federal agency register", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "A facility is removed from the list when it is no longer registered. Check currency, not merely presence." }, { "evidence_id": "EV-0603", "claim": "Section 503B was created by the Drug Quality and Security Act, signed into law on 27 November 2013", "source_title": "Information for Outsourcing Facilities \u2014 Drug Quality and Security Act", "source_url": "https://www.fda.gov/drugs/human-drug-compounding/information-outsourcing-facilities", "source_type": "Federal agency guidance", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0604", "claim": "FDA's registration guidance for outsourcing facilities is issued under docket FDA-2013-N-1429", "source_title": "Registration for Human Drug Compounding Outsourcing Facilities Under Section 503B", "source_url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/registration-human-drug-compounding-outsourcing-facilities-under-section-503b-federal-food-drug-and", "source_type": "Federal agency guidance", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0605", "claim": "FDA's 2019 guidance interpreting clinical need for the 503B bulks list states that clinical need is distinct from supply constraints or cost considerations", "source_title": "FDA Proposes to Exclude GLP-1 Receptor Agonists from the 503B Bulks List \u2014 analysis", "source_url": "https://www.frierlevitt.com/articles/fda-glp1-503b-bulks-list-proposed-exclusion-semaglutide-tirzepatide-liraglutide/", "source_type": "Legal analysis of federal guidance", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Retrieve FDA's 2019 clinical-need guidance directly and cite the agency document rather than this analysis before relying on the wording." }, { "evidence_id": "EV-0606", "claim": "PCAB accreditation is administered through ACHC", "source_title": "503A vs 503B compounding pharmacy \u2014 industry reference", "source_url": "https://tccompound.com/blogs/health-hub/503a-vs-503b", "source_type": "Industry source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Confirm directly with ACHC and capture the public accreditation lookup before describing any provider's PCAB claim as verified." }, { "evidence_id": "EV-0607", "claim": "Reporting indicates FDA issued warning letters to approximately 30 telehealth firms over claims that compounded GLP-1s are identical to branded drugs, with 50 or more warning letters to compounders and distributors during 2025", "source_title": "FDA Proposes to Exclude GLP-1s From 503B Bulk List", "source_url": "https://www.drugtopics.com/view/fda-proposes-to-exclude-glp-1s-from-503b-bulk-list", "source_type": "Trade press", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Counts come from trade press. Verify against FDA's own warning letter database before publishing a number." }, { "evidence_id": "EV-0608", "claim": "Novo Nordisk litigation has alleged that some compounded semaglutide contained impurities at levels up to 86%", "source_title": "FDA Proposes to Exclude GLP-1s From 503B Bulk List", "source_url": "https://www.drugtopics.com/view/fda-proposes-to-exclude-glp-1s-from-503b-bulk-list", "source_type": "Trade press reporting a litigation allegation", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "This is an allegation in litigation by a competitor manufacturer, not an established finding. Do not publish as fact. If used at all, attribute to the litigation and note it is contested." }, { "evidence_id": "EV-0701", "claim": "The Zepbound label directs starting at 2.5 mg once weekly for 4 weeks, increasing to 5 mg, then increasing in 2.5 mg increments no sooner than every 4 weeks, to a maximum of 15 mg once weekly", "source_title": "ZEPBOUND (tirzepatide) US Prescribing Information", "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b", "source_type": "FDA-approved product labelling", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "The label sets a minimum interval, not a fixed calendar. Escalation is based on tolerability and response." }, { "evidence_id": "EV-0702", "claim": "The label states the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage", "source_title": "ZEPBOUND (tirzepatide) US Prescribing Information", "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b", "source_type": "FDA-approved product labelling", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "This is the label's own wording. It is the strongest available support for the point that an advertised price quoted at 2.5 mg is not the price of treatment." }, { "evidence_id": "EV-0703", "claim": "The recommended maintenance dosages are 5 mg, 10 mg or 15 mg once weekly. 7.5 mg and 12.5 mg are titration steps, not recommended maintenance dosages", "source_title": "ZEPBOUND (tirzepatide) US Prescribing Information", "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b", "source_type": "FDA-approved product labelling", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "Correcting an earlier version of our titration table, which presented all six strengths as a sequential schedule." }, { "evidence_id": "EV-0704", "claim": "Zepbound carries a boxed warning for thyroid C-cell tumours observed in rats. Human relevance has not been determined. It is contraindicated in personal or family history of medullary thyroid carcinoma, in Multiple Endocrine Neoplasia syndrome type 2, and in known serious hypersensitivity to tirzepatide or its excipients", "source_title": "ZEPBOUND (tirzepatide) US Prescribing Information", "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b", "source_type": "FDA-approved product labelling", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "Anaphylaxis and angioedema have been reported. Routine calcitonin monitoring or thyroid ultrasound is of uncertain value for early MTC detection, per the label." }, { "evidence_id": "EV-0705", "claim": "The label states that coadministration with other tirzepatide-containing products, or with any GLP-1 receptor agonist, is not recommended", "source_title": "ZEPBOUND (tirzepatide) US Prescribing Information", "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b", "source_type": "FDA-approved product labelling", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "Directly relevant to this market: a patient using a compounded preparation alongside a branded product, or alongside another GLP-1, is doing something the label advises against." }, { "evidence_id": "EV-0706", "claim": "Zepbound is indicated both for chronic weight management and for moderate-to-severe obstructive sleep apnoea in adults with obesity", "source_title": "ZEPBOUND (tirzepatide) US Prescribing Information", "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b", "source_type": "FDA-approved product labelling", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "The OSA indication followed the SURMOUNT-OSA programme." }, { "evidence_id": "EV-0707", "claim": "Zepbound is supplied at 2.5, 5, 7.5, 10, 12.5 and 15 mg per 0.5 mL, administered once weekly at any time of day with or without meals, into the abdomen, thigh or upper arm with site rotation", "source_title": "ZEPBOUND (tirzepatide) US Prescribing Information", "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s003lbl.pdf", "source_type": "FDA-approved product labelling", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0708", "claim": "In SURMOUNT-1, discontinuation due to an adverse event ranged from 4.3% to 7.1% across tirzepatide doses against 2.6% with placebo, and 50% and 57% of the 10 mg and 15 mg groups achieved 20% or greater weight reduction against 3% with placebo", "source_title": "Tirzepatide prescribing guide", "source_url": "https://www.medcentral.com/drugs/guide/tirzepatide", "source_type": "Clinical reference", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary clinical reference. Confirm the discontinuation range and the 20% responder rates against the NEJM publication before relying on them." }, { "evidence_id": "EV-0801", "claim": "FDA issued 25 warning letters on 16 June 2026 to telehealth companies alleging false or misleading website claims about compounded semaglutide, tirzepatide and, in one case, liraglutide", "source_title": "FDA takes aim at misleading online claims for compounded GLP-1 drugs", "source_url": "https://www.lexology.com/library/detail.aspx?g=b1701277-892b-43a9-90cd-529b7263e16e", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0802", "claim": "FDA issued more than 55 warning letters on 16 September 2025 to online sellers of compounded GLP-1s citing misleading direct-to-consumer advertising", "source_title": "FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Takedown", "source_url": "https://www.pharmacytimes.com/view/fda-and-novo-nordisk-warned-of-glp-1-telehealth-compounding-take-down-what-s-next-", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0803", "claim": "FDA issued 30 warning letters to telehealth companies in early 2026 threatening legal action without further notice; Commissioner Makary described it as a new era of enforcement", "source_title": "FDA ramps up crackdown on GLP-1 drug compounding with fresh batch of 30 warning letters", "source_url": "https://www.fiercepharma.com/pharma/fda-ramps-crackdown-glp-1-drug-compounders-fresh-batch-30-warning-letters", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0804", "claim": "On 6 February 2026 FDA announced it would take steps to restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved compounded products", "source_title": "FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs", "source_url": "https://www.pharmacytimes.com/view/fda-and-novo-nordisk-warned-of-glp-1-telehealth-compounding-take-down-what-s-next-", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0805", "claim": "The FDA drug shortage record shows tirzepatide injection determined resolved on 2 October 2024; on 22 October 2024 that decision was remanded to the agency for reevaluation as part of litigation, and on 5 March 2025 a district court denied the plaintiffs' preliminary injunction in Outsourcing Facilities Association v. FDA", "source_title": "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize", "source_url": "https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize", "source_type": "Federal agency record", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0806", "claim": "FDA set 22 May 2025 as the date until which it did not intend to take action against outsourcing facilities for violations depending on semaglutide injection's inclusion on the shortage list", "source_title": "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize", "source_url": "https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize", "source_type": "Federal agency record", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0807", "claim": "As of early 2025 FDA had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 linked to compounded tirzepatide, many involving dosing errors from multidose vials, some requiring hospitalisation", "source_title": "FDA Moves to Permanently Close the Door on Compounded GLP-1s", "source_url": "https://www.pharmacytimes.com/view/fda-moves-to-permanently-close-the-door-on-compounded-glp-1s", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0808", "claim": "A 2026 study found that when tirzepatide is compounded with vitamin B12 the two substances can chemically bond, forming a molecule not present in the FDA-approved product. Compounders commonly add B12, B6, niacinamide, glycine or carnitine, combinations largely untested in clinical trials", "source_title": "Compounded GLP-1s: Why doctors worry and the FDA is cracking down", "source_url": "https://med.stanford.edu/news/insights/2026/07/glp1s-compounded-why-doctors-worry-about-safety.html", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0809", "claim": "TrumpRx launched on 5 February 2026 advertising direct access to lower-cost FDA-approved GLP-1s, listing semaglutide tablets at $149 to $299, semaglutide injections at $199 to $349 and tirzepatide injections at $299 to $449", "source_title": "FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Takedown", "source_url": "https://www.pharmacytimes.com/view/fda-and-novo-nordisk-warned-of-glp-1-telehealth-compounding-take-down-what-s-next-", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0810", "claim": "The FDA Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 to review BPC-157, TB-500 and five other peptides for the 503A compounding list; briefing documents posted 30 June 2026 recommended against adding them", "source_title": "GLP-1 and peptide news digest", "source_url": "https://www.compoundprotocol.com/news", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0811", "claim": "Sandoz and Amneal filed abbreviated new drug applications for generic tirzepatide in 2026; Eli Lilly patents are reported to run to 2036", "source_title": "Generic Tirzepatide: FDA Review and Patent Timeline", "source_url": "https://www.compoundprotocol.com/news", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0812", "claim": "STEP UP reported semaglutide 7.2 mg producing 20.7% weight loss, narrowing the gap with tirzepatide", "source_title": "STEP UP trial digest", "source_url": "https://www.compoundprotocol.com/news", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0813", "claim": "REIMAGINE 2 reported CagriSema reducing HbA1c 1.91 points more than semaglutide alone with 14.2% weight loss in 2,728 adults with type 2 diabetes", "source_title": "REIMAGINE 2 digest", "source_url": "https://www.compoundprotocol.com/news", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0814", "claim": "SOUL reported oral semaglutide reducing major adverse cardiovascular events by 14% and heart failure events by 22% in 9,647 high-risk patients with type 2 diabetes", "source_title": "SOUL trial digest", "source_url": "https://www.compoundprotocol.com/news", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0815", "claim": "EVOKE and EVOKE+ enrolled 3,808 participants over two years and found oral semaglutide made no difference to Alzheimer's disease progression", "source_title": "EVOKE trials digest", "source_url": "https://www.compoundprotocol.com/news", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0816", "claim": "Novo Nordisk reported the Wegovy pill surpassing three million prescriptions in just over five months from its January 2026 launch", "source_title": "FDA approves Novo Nordisk's Wegovy pill", "source_url": "https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-302648344.html", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0901", "claim": "The Interstate Medical Licensure Compact affirms that the practice of medicine occurs where the patient is located at the time of the physician-patient encounter, and that a physician licensed via the compact is under the jurisdiction of the medical board in the state where the patient is located", "source_title": "Interstate Medical Licensure Compact states list and guide", "source_url": "https://comphealth.com/resources/interstate-medical-licensure-compact", "source_type": "Industry or reference source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "This is the governing principle for telehealth prescribing. Verify against the IMLC's own materials before describing as verified." }, { "evidence_id": "EV-0902", "claim": "The IMLC is an expedited pathway to obtaining multiple separate state licences, not a single multistate licence. Each state continues to issue, renew and regulate its own licence", "source_title": "Telehealth Licensure 2025-2026: Cross-State Practice", "source_url": "https://telehealth.org/news/telehealth-licensure-2025-2026-cross-state-practice-and-compacts/", "source_type": "Industry or reference source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0903", "claim": "The IMLC reports 44 member states plus the District of Columbia and Guam as of 2026, with participation levels differing between members", "source_title": "IMLC providing expedited licensure in 44 states in 2026", "source_url": "https://weatherbyhealthcare.com/blog/interstate-medical-licensure-compact", "source_type": "Industry or reference source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Membership changes. Re-check against the IMLC's own list before relying on it." }, { "evidence_id": "EV-0904", "claim": "The Nurse Licensure Compact is a multistate licence, distinct from the IMLC. Source counts differ: one lists 41 member states as of June 2026, another 43 jurisdictions in the enhanced compact as of April 2026", "source_title": "Nurse Licensure Compact member states", "source_url": "https://en.wikipedia.org/wiki/Nurse_Licensure_Compact", "source_type": "Industry or reference source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Two reputable sources give different counts. Both are recorded; neither is presented as settled." }, { "evidence_id": "EV-0905", "claim": "Advanced Practice Registered Nurses are covered by the APRN Compact and physician assistants by the PA Licensure Compact, which are separate from the IMLC", "source_title": "Interstate Medical Licensure Compact: What It Means for You", "source_url": "https://practiceseeker.com/resources/interstate-medical-licensure-compact-what-it-means-for-you", "source_type": "Industry or reference source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-1001", "claim": "SYNERGY-NASH was a phase 2 dose-finding trial of tirzepatide in adults with biopsy-confirmed MASH and stage F2-F3 fibrosis, published as Loomba R et al., N Engl J Med 2024;391(4):299-310, registry NCT04166773", "source_title": "Study Details NCT04166773 \u2014 ClinicalTrials.gov", "source_url": "https://clinicaltrials.gov/study/NCT04166773", "source_type": "Trial registry", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-1002", "claim": "Secondary sources report materially different MASH resolution rates for the 15 mg arm of SYNERGY-NASH: one gives 73.3% against 13.2% placebo, another 62% against 10% placebo", "source_title": "Conflicting secondary coverage of SYNERGY-NASH", "source_url": "https://www.appliedclinicaltrialsonline.com/view/tirzepatide-shows-efficacy-resolving-metabolic-dysfunction-associated-steatohepatitis-without-worsening-of-fibrosis", "source_type": "Trade press or commercial source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Do not publish a single resolution figure until the NEJM full text is read. The discrepancy is the reason." }, { "evidence_id": "EV-1003", "claim": "Tirzepatide is under evaluation for chronic kidney disease and has no completed dedicated kidney outcomes trial. Semaglutide's kidney outcomes evidence comes from the FLOW trial", "source_title": "Tirzepatide Shows Efficacy Resolving MASH \u2014 indications under evaluation", "source_url": "https://www.appliedclinicaltrialsonline.com/view/tirzepatide-shows-efficacy-resolving-metabolic-dysfunction-associated-steatohepatitis-without-worsening-of-fibrosis", "source_type": "Trade press or commercial source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-1004", "claim": "A phase 3 programme, SYNERGY-OUTCOMES, launched in late 2025 with completion targeted for 2032", "source_title": "GLP-1s and fatty liver disease \u2014 pipeline summary", "source_url": "https://thepeptidecatalog.com/articles/glp1-fatty-liver-mash-fda-approved", "source_type": "Trade press or commercial source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Source is a commercial peptide site and also asserts tirzepatide is FDA-approved for MASH, which conflicts with trade coverage describing it as under evaluation. Treat all claims from this source as unverified." }, { "evidence_id": "EV-1101", "claim": "NexLife states that it serves patients nationwide across all 50 states", "source_title": "NexLife \u2014 tirzepatide plans", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider's own published page", "capture_date": "2026-07-11", "reviewer": "Editorial research desk", "archive": "archives/nexlife-plans-2026-07-11.png", "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-11", "notes": "This is NexLife's own stated position, captured from its published page. We report it as the provider's claim. Confirming it for a given state additionally requires prescriber licensure, pharmacy dispensing authority and current intake eligibility in that state, which we have not checked." } ]